慢性淋巴细胞白血病免疫球蛋白基因序列分析:ERIC(欧洲慢性淋巴细胞白血病研究倡议)2022年推荐更新
该更新由ERIC制定,阐述免疫球蛋白重链可变区(IGHV)基因体细胞超突变(SHM)状态是慢性淋巴细胞白血病(CLL)预后及治疗反应预测的关键生物标志物,并指出不同患者可表达(准)相同的定型B细胞受体免疫球蛋白(BcR IG)并据此分为亚型,某些定型亚型具有一致的生物学、临床表现和结局。更新还指出原有推荐针对Sanger测序,而下一代测序(NGS)正日益取代之,故需更新分析推荐以辅助CLL患者的精细管理。
要点
- IGHV基因SHM状态是CLL预后及对化学免疫治疗(CIT)和新型靶向药物反应预测的关键生物标志物。
- 不同CLL患者可表达(准)相同的定型BcR IG,并据此分为亚型,某些亚型具有一致的生物学、临床表现和结局,即使IGHV基因SHM状态一致。
- ERIC原有免疫遗传分析推荐覆盖分析前、分析中及分析后各阶段,但针对Sanger测序,现需更新以适应NGS的日益应用。
核心结论
- IGHV基因SHM状态是CLL预后评估的关键生物标志物,也是对化学免疫治疗(CIT)和新型靶向药物反应的预测因素。
- 免疫遗传分析是CLL准确风险分层和临床决策的基石,ERIC更新分析推荐以辅助CLL患者的精细管理。
研究设计与样本
- ERIC(欧洲慢性淋巴细胞白血病研究倡议)制定的2022年推荐更新,基于对免疫遗传学在CLL中临床效用及分析推荐的更新。
主要发现
- 独立研究记录IGHV SHM状态可预测对化学免疫治疗(CIT)和新型靶向药物的反应。
- 不同CLL患者可表达(准)相同的定型BcR IG,并据此分为亚型;某些定型亚型患者具有一致的生物学、临床表现和结局,即使IGHV基因SHM状态一致。
- ERIC原有推荐覆盖分析前、分析中及分析后各阶段,涉及分析、解读和报告,但针对Sanger测序,而NGS正日益取代Sanger测序。
关键数值与推荐
- IGHV基因SHM状态作为CLL预后生物标志物及对CIT和新型靶向药物反应的预测因素。
- 基于(准)相同定型BcR IG表达将患者分为亚型,某些亚型具有一致的生物学、临床表现和结局,独立于IGHV SHM状态。
- ERIC推荐覆盖分析前、分析中及分析后各阶段,涉及分析、解读和报告;原推荐针对Sanger测序,现更新以适应NGS。
临床怎么用
- 原文未据此给出具体临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The somatic hypermutation (SHM) status of the clonotypic immunoglobulin heavy variable (IGHV) gene is a critical biomarker for assessing the prognosis of patients with chronic lymphocytic leukemia (CLL). Importantly, independent studies have documented that IGHV SHM status is also a predictor of responses to therapy, including both chemoimmunotherapy (CIT) and novel, targeted agents. Moreover, immunogenetic analysis in CLL has revealed that different patients may express (quasi)identical, stereotyped B cell receptor immunoglobulin (BcR IG) and are classified into subsets based on this common feature. Patients in certain stereotyped subsets display consistent biology, clinical presentation, and outcome that are distinct from other patients, even with concordant IGHV gene SHM status. All of the above highlights the relevance of immunogenetic analysis in CLL, which is considered a cornerstone for accurate risk stratification and clinical decision making. Recommendations for robust immunogenetic analysis exist thanks to dedicated efforts by ERIC, the European Research Initiative on CLL, covering all test phases, from the pre-analytical and analytical to the post-analytical, pertaining to the analysis, interpretation, and reporting of the findings. That said, these recommendations apply to Sanger sequencing, which is increasingly being superseded by next generation sequencing (NGS), further underscoring the need for an update. Here, we present an overview of the clinical utility of immunogenetics in CLL and update our analytical recommendations with the aim to assist in the refined management of patients with CLL.
引用
- Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia. 2022. PMID: 35614318. doi:10.1038/s41375-022-01604-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。